Til StÃ¼rmer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6800020/publications.pdf

Version: 2024-02-01

261 papers	14,601 citations	28274 55 h-index	22166 113 g-index
271 all docs	271 docs citations	271 times ranked	18163 citing authors

#	Article	IF	Citations
1	Longâ€Term Mortality of Patients With Osteoarthritis After Joint Replacement: Prognostic Value of Preoperative and Postoperative Pain and Function. Arthritis Care and Research, 2023, 75, 869-875.	3.4	3
2	Impacts of Initial Prescription Length and Prescribing Limits on Risk of Prolonged Postsurgical Opioid Use. Medical Care, 2022, 60, 75-82.	2.4	6
3	Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators. Pharmacoepidemiology and Drug Safety, 2022, 31, 261-269.	1.9	32
4	Comparison of approaches for measuring adherence and persistence to oral oncologic therapies in patients diagnosed with metastatic renal cell carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.0341.2021.	2.5	0
5	Cardiovascular Effectiveness of Sodiumâ€Glucose Cotransporter 2 Inhibitors and Glucagonâ€Like Peptideâ€1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association, 2022, 11, e022376.	3.7	14
6	Veterinary antimicrobial prescribing practices for treatment of presumptive sporadic urinary tract infections in dogs examined at primary care practices in the United States (2010â€“2019). Journal of the American Veterinary Medical Association, 2022, , 1-7.	0.5	3
7	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes, 2022, , 1.	1.6	16
8	Alternative analytic and matching approaches for the prevalent newâ€user design: A simulation study. Pharmacoepidemiology and Drug Safety, 2022, 31, 796-803.	1.9	3
9	Considerations for Observational Study Design: Comparing the Evidence of Opioid Use between Electronic Health Records and Insurance Claims.. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	2
10	The impact of diabetes on the performance of skeletal muscle density (SMD) in screening for frailty: Findings from the Cancer and Aging Resilience Evaluation (CARE) Registry.. Journal of Clinical Oncology, 2022, 40, 12037-12037.	1.6	0
11	Ondansetron use in early pregnancy and the risk of miscarriage. Pharmacoepidemiology and Drug Safety, 2021, 30, 103-113.	1.9	6
12	Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. Pharmacoepidemiology and Drug Safety, 2021, 30, 114-125.	1.9	6
13	Quantifying cumulative anticholinergic and sedative drug load among US Medicare Beneficiaries. Pharmacoepidemiology and Drug Safety, 2021, 30, 144-156.	1.9	4
14	Gender Disparities in Surgical Treatment of Axis Fractures in Older Adults. Global Spine Journal, 2021, 11, 71-75.	2.3	1
15	Medicaid and Medicare. Springer Series on Epidemiology and Public Health, 2021, , 231-242.	0.5	0
16	Unmeasured confounding with and without randomization. , 2021, , 185-205.		0
17	â€œThe Heidelberg Fiveâ€•personality dimensions: Genomeâ€wide associations, polygenic risk for neuroticism, and psychopathology 20â€‰years after assessment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 77-89.	1.7	6
18	Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: A plasmode simulation. Statistics in Medicine, 2021, 40, 2101-2112.	1.6	10

#	Article	IF	Citations
19	Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis. Annals of Internal Medicine, 2021, 174, 737-746.	3.9	11
20	Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. American Journal of Epidemiology, 2021, 190, 1659-1670.	3.4	31
21	Introducing longitudinal cumulative dose to describe chemotherapy patterns over time: Case study of a colon cancer trial. International Journal of Cancer, 2021, 149, 394-402.	5.1	6
22	Methodologies for Validation of Diagnoses in Real-World Data: BONESâ€"A Case Study. Journal of Orthopaedic Trauma, 2021, 35, S28-S32.	1.4	2
23	Using randomized trial data to estimate effects of complex treatment regimens in real-world patients.. Journal of Clinical Oncology, 2021, 39, e18706-e18706.	1.6	0
24	Comparing FOLFOX delivery in trial and real-world populations using longitudinal cumulative dose.. Journal of Clinical Oncology, 2021, 39, 1521-1521.	1.6	0
25	Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodiumâ€"Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes. Diabetes Care, 2021, 44, 1564-1572.	8.6	43
26	Effects of anticholinergic and sedative medication use on fractures: A <scp>selfâ€controlled</scp> design study. Journal of the American Geriatrics Society, 2021, 69, 3212-3224.	2.6	8
27	Day-of-Surgery Gabapentinoids and Prolonged Opioid Use: A Retrospective Cohort Study of Medicare Patients Using Electronic Health Records. Anesthesia and Analgesia, 2021, 133, 1119-1128.	2.2	4
28	When Is a Growth-friendly Strategy Warranted? A Matched Comparison of Growing Rods Versus Primary Posterior Spinal Fusion in Juveniles With Early-onset Scoliosis. Journal of Pediatric Orthopaedics, 2021, 41, e859-e864.	1.2	12
29	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in Medicine, 2021, 40, 1718-1735.	1.6	50
30	Interplay between the genetics of personality traits, severe psychiatric disorders and COVID-19 host genetics in the susceptibility to SARS-CoV-2 infection. BJPsych Open, 2021, 7, e188.	0.7	1
31	Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. JAMA Network Open, 2021, 4, e2132215.	5.9	9
32	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiology and Drug Safety, 2020, 29, 9-17.	1.9	34
33	Methodological considerations when analysing and interpreting real-world data. Rheumatology, 2020, 59, 14-25.	1.9	50
34	The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics. Scientific Reports, 2020, 10, 17282.	3.3	9
35	Effectiveness of adjuvant <scp>FOLFOX</scp> vs <scp>5FU</scp>/<scp>LV</scp> in adults over age 65 with stage <scp>II</scp> and <scp>III</scp> colon cancer using a novel hybrid approach. Pharmacoepidemiology and Drug Safety, 2020, 29, 1579-1587.	1.9	3
36	Real-world evidence: the devil is in the detail. Diabetologia, 2020, 63, 1694-1705.	6.3	38

#	Article	IF	Citations
37	Realâ€world onâ€treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. Pharmacoepidemiology and Drug Safety, 2020, 29, 832-841.	1.9	4
38	Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation. Epidemiology, 2020, 31, 605-613.	2.7	9
39	1-Year Mortality and Surgery Incidence in Older US Adults with Cervical Spine Fracture. World Neurosurgery, 2020, 141, e858-e863.	1.3	5
40	Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournierâ€™s gangrene. BMJ Open Diabetes Research and Care, 2020, 8, e000985.	2.8	19
41	Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107706.	2.3	3
42	Five yearsâ€™ trajectories of functionality and pain in patients after hip or knee replacement and association with long-term patient survival. Scientific Reports, 2020, 10, 14388.	3.3	5
43	Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. Diabetes Care, 2020, 43, 2121-2127.	8.6	7
44	Association Between an Acute, Drug-Induced Decrease in High-Density Lipoprotein Cholesterol Levels and Risk of Cardiovascular Events. Clinical Drug Investigation, 2020, 40, 747-754.	2.2	1
45	Comparative Propensity-Weighted Mortality After Isolated Acute Traumatic Axis Fractures in Older Adults. Geriatric Orthopaedic Surgery and Rehabilitation, 2020, 11, 215145932091186.	1.4	2
46	Single-arm Trials With External Comparators and Confounder Misclassification. Medical Care, 2020, 58, 1116-1121.	2.4	9
47	Perspectives on the Future of Epidemiology: A Framework for Training. American Journal of Epidemiology, 2020, 189, 634-639.	3.4	7
48	Longitudinal cumulative dose: A novel measure to assess multiple dimensions of chemotherapy adherence over time.. Journal of Clinical Oncology, 2020, 38, 3522-3522.	1.6	0
49	Effectiveness of adjuvant FOLFOX versus 5FU for colon cancer treatment in community oncology practice using a hybrid study approach.. Journal of Clinical Oncology, 2020, 38, 7067-7067.	1.6	0
50	Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women. Rheumatology, 2020, 59, 2502-2511.	1.9	2
51	Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth. Journal of Adolescent Health, 2019, 65, 536-542.	2.5	9
52	Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointestinal Endoscopy, 2019, 90, 360-369.	1.0	35
53	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiology and Drug Safety, 2019, 28, 1290-1298.	1.9	19
54	Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand. Pharmacoepidemiology and Drug Safety, 2019, 28, 1609-1619.	1.9	10

#	Article	IF	Citations
55	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. Diabetes Care, 2019, 42, 2065-2074.	8.6	8
56	Genome-Wide Association Study of Apparent Treatment-Resistant Hypertension in the CHARGE Consortium: The CHARGE Pharmacogenetics Working Group. American Journal of Hypertension, 2019, 32, 1146-1153.	2.0	17
57	Sodiumâ€glucose coâ€transporterâ€2 inhibitor use and risk of lowerâ€extremity amputation: Evolving questions, evolving answers. Diabetes, Obesity and Metabolism, 2019, 21, 1223-1236.	4.4	29
58	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. Journal of the American Society of Nephrology: JASN, 2019, 30, 346-353.	6.1	29
59	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. Diabetes Care, 2019, 42, e89-e91.	8.6	6
60	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with typeâ€2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2096-2106.	4.4	6
61	Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposuresâ€”Beyond Avoiding Immortal Person-Time. American Journal of Epidemiology, 2019, 188, 1016-1022.	3.4	6
62	Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 728-737.	4.5	24
63	Restriction of Pharmacoepidemiologic Cohorts to Initiators of Medications in Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults. American Journal of Epidemiology, 2019, 188, 1371-1382.	3.4	8
64	Pharmacoepidemiology and Drug Safety's special issue on validation studies. Pharmacoepidemiology and Drug Safety, 2019, 28, 123-125.	1.9	8
65	Diagnostic Assessment of Assumptions for External Validity. Epidemiology, 2019, 30, 103-111.	2.7	12
66	Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. Medical Care, 2019, 57, 286-294.	2.4	13
67	Reninâ€“Angiotensinâ€“Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries. Epidemiology, 2019, 30, 867-875.	2.7	16
68	Causeâ€specific mortality among Medicare beneficiaries with newly diagnosed nonâ€Hodgkin lymphoma subtypes. Cancer, 2019, 125, 1101-1112.	4.1	16
69	Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiology and Drug Safety, 2019, 28, 305-314.	1.9	1
70	Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 100-106.	1.3	5
71	Impact of metformin use on the cardiovascular effects of dipeptidyl peptidaseâ€4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. Diabetes, Obesity and Metabolism, 2019, 21, 854-865.	4.4	6
72	Association Between Postoperative Delirium and Long-term Cognitive Function After Major Nonemergent Surgery. JAMA Surgery, 2019, 154, 328.	4.3	51

#	Article	IF	Citations
73	Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children. Depression and Anxiety, 2019, 36, 179-189.	4.1	10
74	Comparison of Methods to Generalize Randomized Clinical Trial Results Without Individual-Level Data for the Target Population. American Journal of Epidemiology, 2019, 188, 426-437.	3.4	16
75	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. Diabetes Care, 2019, 42, e21-e23.	8.6	17
76	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. American Journal of Epidemiology, 2019, 188, 609-616.	3.4	25
77	Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. JAMA Pediatrics, 2019, 173, 160.	6.2	36
78	Position matters: Validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1085-1091.	1.9	9
79	Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders. Medical Care, 2018, 56, 510-519.	2.4	7
80	Classifying medical histories in US Medicare beneficiaries using fixed vs allâ€available lookâ€back approaches. Pharmacoepidemiology and Drug Safety, 2018, 27, 771-780.	1.9	17
81	The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. Diabetes Care, 2018, 41, 1196-1203.	8.6	6
82	Injection testosterone and adverse cardiovascular events: AÂcaseâ€crossover analysis. Clinical Endocrinology, 2018, 88, 719-727.	2.4	8
83	Considerations for Pharmacoepidemiological Studies of Drugâ€“Cancer Associations. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 451-459.	2.5	70
84	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 129-140.	4.4	14
85	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensinâ€Converting Enzyme Inhibitors or Angiotensin <scp>II</scp> Receptor Blockers after an Acute Myocardial Infarction. Pharmacotherapy, 2018, 38, 29-41.	2.6	8
86	Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 41-49.	2.5	29
87	Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population. American Journal of Epidemiology, 2018, 187, 817-827.	3.4	23
88	Approaches to Address Premature Death of Patients When Assessing Patterns of Use of Health Care Services After an Index Event. Medical Care, 2018, 56, 619-625.	2.4	3
89	Who diagnosed and prescribed what? Using provider details to inform observational research. Pharmacoepidemiology and Drug Safety, 2018, 27, 1422-1426.	1.9	5
90	Principles and considerations for effective academia-industry collaboration in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2018, 27, 1153-1156.	1.9	1

#	Article	IF	Citations
91	Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry,the, 2018, 5, 824-835.	7.4	187
92	Controlling for Frailty in Pharmacoepidemiologic Studies of Older Adults. Epidemiology, 2018, 29, 556-561.	2.7	32
93	The importance and implications of comparator selection in pharmacoepidemiologic research. Current Epidemiology Reports, 2018, 5, 272-283.	2.4	29
94	Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. Pharmacoepidemiology and Drug Safety, 2018, 27, 857-866.	1.9	8
95	Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. Diabetes Care, 2018, 41, 1998-2009.	8.6	32
96	Treating Pediatric Anxiety. Journal of Clinical Psychiatry, 2018, 79, 16m11415.	2.2	27
97	Using Procedure Codes to Define Radiation Toxicity in Administrative Data. Medical Care, 2017, 55, e36-e43.	2.4	2
98	No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidaseâ€4 inhibitors vs therapeutic alternatives. Diabetes, Obesity and Metabolism, 2017, 19, 970-978.	4.4	17
99	A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Journal of Medical Genetics, 2017, 54, 313-323.	3.2	9
100	Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. Pharmacoepidemiology and Drug Safety, 2017, 26, 666-675.	1.9	2
101	Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women. Epidemiology, 2017, 28, 446-454.	2.7	15
102	Antihypertensive Adherence Trajectories Among Older Adults in the First Year After Initiation of Therapy. American Journal of Hypertension, 2017, 30, 1015-1023.	2.0	21
103	Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014. JAMA Psychiatry, 2017, 74, 747.	11.0	64
104	External adjustment of unmeasured confounders in a caseâ€“control study of benzodiazepine use and cancer risk. British Journal of Clinical Pharmacology, 2017, 83, 2517-2527.	2.4	6
105	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1141.	7.4	250
106	The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality. Pharmacoepidemiology and Drug Safety, 2017, 26, 446-458.	1.9	1
107	Controlling confounding by frailty when estimating influenza vaccine effectiveness using predictors of dependency in activities of daily living. Pharmacoepidemiology and Drug Safety, 2017, 26, 1500-1506.	1.9	15
108	Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. International Archives of Allergy and Immunology, 2017, 173, 51-60.	2.1	16

#	Article	IF	Citations
109	The â€œDry-Runâ€•Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	3.4	15
110	Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants. Journal of Pediatrics, 2017, 180, 99-104.e1.	1.8	46
111	Initiation of antihypertensive monotherapy and incident fractures among Medicare beneficiaries. Injury Epidemiology, 2017, 4, 27.	1.8	9
112	Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding. Clinical Epidemiology, 2017, Volume 9, 611-626.	3.0	41
113	More realistic power estimation for new user, active comparator studies: an empirical example. Pharmacoepidemiology and Drug Safety, 2016, 25, 462-466.	1.9	2
114	Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety, 2016, 25, 512-520.	1.9	14
115	Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. Pharmacoepidemiology and Drug Safety, 2016, 25, 836-843.	1.9	6
116	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.2	28
117	Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. European Journal of Clinical Pharmacology, 2016, 72, 1013-1023.	1.9	13
118	Trends in Prevalence and Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012. Journal of the American Geriatrics Society, 2016, 64, 788-797.	2.6	105
119	Predicting persistence to antidepressant treatment in administrative claims data: Considering the influence of refill delays and prior persistence on other medications. Journal of Affective Disorders, 2016, 196, 138-147.	4.1	19
120	Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. Journal of Geriatric Oncology, 2016, 7, 176-186.	1.0	8
121	Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. American Journal of Men's Health, 2016, 10, 399-407.	1.6	16
122	Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning. Psychiatric Services, 2016, 67, 302-309.	2.0	18
123	Tamoxifen Initiation After Ductal Carcinoma In Situ. Oncologist, 2016, 21, 134-140.	3.7	24
124	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. Journal of the American Society of Nephrology: JASN, 2016, 27, 3129-3138.	6.1	50
125	Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use. Translational Cancer Research, 2016, 5, S1131-S1134.	1.0	0
126	Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1102-1110.	4.9	9

#	Article	IF	Citations
127	The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application. Current Epidemiology Reports, 2015, 2, 221-228.	2.4	407
128	Short look-back periods in pharmacoepidemiologic studies of new users of antibiotics and asthma medications introduce severe misclassification. Pharmacoepidemiology and Drug Safety, 2015, 24, 478-485.	1.9	13
129	Matching on the disease risk score in comparative effectiveness research of new treatments. Pharmacoepidemiology and Drug Safety, 2015, 24, 951-961.	1.9	29
130	Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiology and Drug Safety, 2015, 24, 59-66.	1.9	132
131	Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults. Epidemiology, 2015, 26, 690-699.	2.7	16
132	Validation of Medicaid Claims-based Diagnosis of Myocardial Infarction Using an HIV Clinical Cohort. Medical Care, 2015, 53, e41-e48.	2.4	15
133	Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium. PLoS ONE, 2015, 10, e0140496.	2.5	15
134	Trends and Determinants of Oral Anti-Diabetic Initiation in Youth with Suspected Type 2 Diabetes. PLoS ONE, 2015, 10, e0140611.	2.5	1
135	Antidepressant Dose and Risk of Deliberate Self-harmâ€"Reply. JAMA Internal Medicine, 2015, 175, 464.	5.1	3
136	Metformin and the risk of endometrial cancer: A population-based cohort study. Gynecologic Oncology, 2015, 136, 341-347.	1.4	40
137	Serotoninâ€"Norepinephrine Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor Use and Risk of Fractures: A New-User Cohort Study Among US Adults Aged 50 Years and Older. CNS Drugs, 2015, 29, 245-252.	5.9	31
138	An Observational Study of Pharmacological Treatment in Primary Care of Children With ADHD in the United Kingdom. Psychiatric Services, 2015, 66, 617-624.	2.0	22
139	SSRI use and risk of fractures among perimenopausal women without mental disorders. Injury Prevention, 2015, 21, 397-403.	2.4	40
140	Comparative Safety of Testosterone Dosage Forms. JAMA Internal Medicine, 2015, 175, 1187.	5.1	76
141	Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. JAMA Pediatrics, 2015, 169, 452.	6.2	119
142	Misinterpretation of the Comparative Safety of Testosterone Dosage Formsâ€"Reply. JAMA Internal Medicine, 2015, 175, 1875.	5.1	1
143	The Role of Prediction Modeling in Propensity Score Estimation: An Evaluation of Logistic Regression, bCART, and the Covariate-Balancing Propensity Score. American Journal of Epidemiology, 2014, 180, 645-655.	3.4	81
144	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	12.8	216

#	Article	IF	Citations
145	Childbearing is not associated with young women's longâ€term obesity risk. Obesity, 2014, 22, 1126-1132.	3.0	17
146	Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. Journal of Internal Medicine, 2014, 275, 570-580.	6.0	214
147	Measures of â€˜exposure needed for one additional patient to be harmedâ€™ in populationâ€based caseâ€control studies. Pharmacoepidemiology and Drug Safety, 2014, 23, 868-874.	1.9	12
148	Use of Combination Antihypertensive Therapy Initiation in Older Americans without Prevalent Cardiovascular Disease. Journal of the American Geriatrics Society, 2014, 62, 1729-1735.	2.6	2
149	Antidepressant Dose, Age, and the Risk of Deliberate Self-harm. JAMA Internal Medicine, 2014, 174, 899.	5.1	76
150	Association Between the Choice of IV Crystalloid and In-Hospital Mortality Among Critically Ill Adults With Sepsis*. Critical Care Medicine, 2014, 42, 1585-1591.	0.9	340
151	Evidence of Sample Use Among New Users of Statins. Medical Care, 2014, 52, 773-780.	2.4	33
152	Trends in Glyburide Compared With Insulin Use for Gestational Diabetes Treatment in the United States, 2000â€“2011. Obstetrics and Gynecology, 2014, 123, 1177-1184.	2.4	79
153	Assessing the Impact of Propensity Score Estimation and Implementation on Covariate Balance and Confounding Control Within and Across Important Subgroups in Comparative Effectiveness Research. Medical Care, 2014, 52, 280-287.	2.4	9
154	Effects of Combination Antiretroviral Therapies on the Risk of Myocardial Infarction Among HIV Patients. Epidemiology, 2014, 25, 406-417.	2.7	26
155	Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2014, 59, 1535-1543.	2.3	25
156	Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 835-842.	3.6	168
157	International Society for Pharmacoepidemiology (ISPE) statement on American Society of Clinical Oncology's new policy for relationships with companies. Pharmacoepidemiology and Drug Safety, 2014, 23, 1-2.	1.9	3
158	The challenges of comparing results between placebo controlled randomized trials and nonâ€experimental new user, active comparator cohort studies: the example of olmesartan. Pharmacoepidemiology and Drug Safety, 2014, 23, 357-360.	1.9	2
159	Direct, Indirect, Total, and Overall Effectiveness of the Rotavirus Vaccines for the Prevention of Gastroenteritis Hospitalizations in Privately Insured US Children, 2007-2010. American Journal of Epidemiology, 2014, 179, 895-909.	3.4	37
160	Reducing Bias Amplification in the Presence of Unmeasured Confounding through Out-of-Sample Estimation Strategies for the Disease Risk Score. Journal of Causal Inference, 2014, 2, 131-146.	1.2	17
161	Model Misspecification When Excluding Instrumental Variables from PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. Epidemiologic Methods, 2014, 3, 83-96.	0.9	1
162	Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin. PLoS ONE, 2014, 9, e109433.	2.5	6

#	Article	IF	Citations
163	Initial therapy with transarterial chemoembolization (TACE) versus Yttrium⁹⁰ radioembolization (Y⁹⁰) for hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2014, 32, e15131-e15131.	1.6	0
164	Comparative effectiveness of contemporary adjuvant chemotherapy among older rectal cancer patients.. Journal of Clinical Oncology, 2014, 32, 3579-3579.	1.6	0
165	Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Medical Research Methodology, 2013, 13, 142.	3.1	19
166	Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients. Cancer, 2013, 119, 2038-2047.	4.1	16
167	The incident user design in comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2013, 22, 1-6.	1.9	181
168	Variable selection for propensity score models when estimating treatment effects on multiple outcomes: a simulation study. Pharmacoepidemiology and Drug Safety, 2013, 22, 77-85.	1.9	71
169	Temporal Trends in Medical Therapies for ST- and Non-ST Elevation Myocardial Infarction: (from the) Tj ETQq1 1 0.784314 rgBT /Overl 111, 305-311.	1.6	11
170	Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Annals of Epidemiology, 2013, 23, 204-209.	1.9	5
171	Effect of Statin Use on Acute Kidney Injury Risk Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2013, 111, 823-828.	1.6	56
172	Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. Diabetes Care, 2013, 36, 3517-3525.	8.6	40
173	Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Injury Prevention, 2013, 19, 164-170.	2.4	37
174	Propensity Score Methods for Confounding Control in Nonexperimental Research. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 604-611.	2.2	435
175	Comparative Effectiveness of Intensity-Modulated Radiotherapy and Conventional Conformal Radiotherapy in the Treatment of Prostate Cancer After Radical Prostatectomy. JAMA Internal Medicine, 2013, 173, 1136.	5.1	40
176	Approaches to Antifungal Therapies and Their Effectiveness among Patients with Cryptococcosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2485-2495.	3.2	36
177	Calendar timeâ€specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiology and Drug Safety, 2013, 22, 810-818.	1.9	50
178	Acute kidney injury in statin initiators. Pharmacoepidemiology and Drug Safety, 2013, 22, 1061-1070.	1.9	12
179	Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. Pharmacoepidemiology and Drug Safety, 2013, 22, 138-144.	1.9	13
180	Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 122-129.	1.9	44

#	Article	IF	Citations
181	Identifying Specific Chemotherapeutic Agents in Medicare Data. Medical Care, 2013, 51, e27-e34.	2.4	68
182	Hospitalization and Skilled Nursing Care are Predictors of Influenza Vaccination Among Patients on Hemodialysis. Medical Care, 2013, 51, 1106-1113.	2.4	11
183	Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006â€“2010. PLoS ONE, 2013, 8, e73825.	2.5	33
184	Propensity Score Estimation to Address Calendar Time-Specific Channeling in Comparative Effectiveness Research of Second Generation Antipsychotics. PLoS ONE, 2013, 8, e63973.	2.5	7
185	Comparative Effectiveness of Oxaliplatin vs Nonâ€“Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 211-227.	6.3	90
186	Treating Depression After Initial Treatment Failure. Journal of Clinical Psychopharmacology, 2012, 32, 114-119.	1.4	69
187	Propensity Score Calibration in the Absence of Surrogacy. American Journal of Epidemiology, 2012, 175, 1294-1302.	3.4	23
188	Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years. Journal of Clinical Oncology, 2012, 30, 2624-2634.	1.6	215
189	Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1611.	7.4	392
190	Lumbar spine radiographic features and demographic, clinical, and radiographic knee, hip, and hand osteoarthritis. Arthritis Care and Research, 2012, 64, 1536-1544.	3.4	53
191	A framework for understanding cancer comparative effectiveness research data needs. Journal of Clinical Epidemiology, 2012, 65, 1150-1158.	5.0	26
192	Comparative Health-Care Cost Advantage of Ipratropium over Tiotropium in COPD Patients. Value in Health, 2012, 15, 269-276.	0.3	1
193	Statins are associated with reduced use of steroids in inflammatory bowel disease: A retrospective cohort study*. Inflammatory Bowel Diseases, 2012, 18, 1048-1056.	1.9	61
194	Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer, 2012, 118, 2925-2934.	4.1	21
195	Data for cancer comparative effectiveness research. Cancer, 2012, 118, 5186-5197.	4.1	25
196	Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry, 2012, 34, 192-200.	2.4	11
197	Opioid Analgesics and the Risk of Fractures in Older Adults with Arthritis. Journal of the American Geriatrics Society, 2011, 59, 430-438.	2.6	176
198	The role of the câ€statistic in variable selection for propensity score models. Pharmacoepidemiology and Drug Safety, 2011, 20, 317-320.	1.9	128

#	Article	IF	Citations
199	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiology and Drug Safety, 2011, 20, 551-559.	1.9	111
200	Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?. Depression and Anxiety, 2011, 28, 989-998.	4.1	12
201	Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data. Inflammatory Bowel Diseases, 2011, 17, 787-794.	1.9	13
202	Doubly Robust Estimation of Causal Effects. American Journal of Epidemiology, 2011, 173, 761-767.	3.4	671
203	Nonexperimental Comparative Effectiveness Research Using Linked Healthcare Databases. Epidemiology, 2011, 22, 298-301.	2.7	64
204	Nocturnal sleep duration and cognitive impairment in a populationâ€based study of older adults. International Journal of Geriatric Psychiatry, 2010, 25, 100-109.	2.7	68
205	Confounding Control in Healthcare Database Research. Medical Care, 2010, 48, S114-S120.	2.4	291
206	Depressive Symptoms, Social Support, and Risk of Adult Asthma in a Population-Based Cohort Study. Psychosomatic Medicine, 2010, 72, 309-315.	2.0	39
207	Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiology and Drug Safety, 2010, 19, 2-9.	1.9	47
208	Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiology and Drug Safety, 2010, 19, 1248-1255.	1.9	82
209	Is the Whole Greater Than the Sum of Its Parts?. Journal of Rheumatology, 2010, 37, 1794-1796.	2.0	1
210	Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study. American Journal of Epidemiology, 2010, 172, 843-854.	3.4	343
211	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	3.4	71
212	The Future of Epidemiology. Academic Medicine, 2009, 84, 1631-1637.	1.6	24
213	A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2792-2798.	3.6	86
214	Strengthening Howick's Argument Against The Alleged Superiority of Placebo-Controlled Trials. American Journal of Bioethics, 2009, 9, 62-64.	0.9	3
215	ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research: Benefit or Harm?. Value in Health, 2009, 12, 1042-1043.	0.3	3
216	Pharmacoepidemiology and â€œin silicoâ€•drug evaluation: is there common ground?. Journal of Clinical Epidemiology, 2008, 61, 205-206.	5.0	5

#	Article	IF	Citations
217	Obesity and Adult Asthma: Potential Effect Modification by Gender, But Not by Hay Fever. Annals of Epidemiology, 2008, 18, 283-289.	1.9	43
218	Relative Effectiveness of Osteoporosis Drugs for Preventing Nonvertebral Fracture. Annals of Internal Medicine, 2008, 148, 637.	3.9	82
219	The Role of the <i>TPH1</i> and <i>TPH2</i> Genes for Nicotine Dependence: A Genetic Association Study in Two Different Age Cohorts. Neuropsychobiology, 2007, 56, 47-54.	1.9	20
220	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". American Journal of Epidemiology, 2007, 165, 1122-1123.	3.4	14
221	Performance of Propensity Score Calibration--A Simulation Study. American Journal of Epidemiology, 2007, 165, 1110-1118.	3.4	101
222	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. Medical Care, 2007, 45, S131-S142.	2.4	228
223	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. Medical Care, 2007, 45, S158-S165.	2.4	68
224	Aspirin and Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: Weighing the Evidence. Annals of Internal Medicine, 2007, 147, 674.	3.9	0
225	Colorectal Cancer After Start of Nonsteroidal Anti-Inflammatory Drug Use. American Journal of Medicine, 2006, 119, 494-502.	1.5	26
226	A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 2006, 59, 437.e1-437.e24.	5.0	557
227	Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiology and Drug Safety, 2006, 15, 698-709.	1.9	96
228	Indications for Propensity Scores and Review of their Use in Pharmacoepidemiology. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 253-259.	2.5	474
229	The course of high-sensitive C-reactive protein in correlation with pain and clinical function in patients with acute lumbosciatic pain and chronic low back pain-A 6 months prospective longitudinal study. European Journal of Pain, 2006, 10, 711-711.	2.8	51
230	Diabetes and cognitive function in a population-based study of elderly women and men. Journal of Diabetes and Its Complications, 2006, 20, 238-245.	2.3	27
231	Personality, lifestyle, and risk of cardiovascular disease and cancer: follow-up of population based cohort. BMJ: British Medical Journal, 2006, 332, 1359.	2.3	92
232	Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2391-2397.	2.5	113
233	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	3.4	1,618
234	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. American Journal of Epidemiology, 2005, 162, 279-289.	3.4	185

#	Article	IF	Citations
235	Pain and high sensitivity C reactive protein in patients with chronic low back pain and acute sciatic pain. Annals of the Rheumatic Diseases, 2005, 64, 921-925.	0.9	82
236	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. American Journal of Epidemiology, 2005, 161, 891-898.	3.4	155
237	A computer program to estimate power and relative efficiency of flexibly matched case-control studies. Methods of Information in Medicine, 2005, 44, 693-6.	1.2	0
238	A computer program to estimate power and relative efficiency to assess multiplicative interactions in flexibly matched case-control studies. Computer Methods and Programs in Biomedicine, 2004, 74, 261-265.	4.7	3
239	Prevalence and determinants of antibiotic resistance in faecalEscherichia coli among unselected patients attending general practitioners in Southwest Germany. Pharmacoepidemiology and Drug Safety, 2004, 13, 303-308.	1.9	11
240	Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Annals of the Rheumatic Diseases, 2004, 63, 200-205.	0.9	160
241	Estrogens and breast cancer: does timing really matter?. Journal of Clinical Epidemiology, 2004, 57, 763-765.	5.0	1
242	Relation among alcohol dehydrogenase 2 polymorphism, alcohol consumption, and levels of gamma-glutamyltransferase. Alcohol, 2003, 29, 131-135.	1.7	16
243	Provider Delay Among Patients With Breast Cancer in Germany: A Population-Based Study. Journal of Clinical Oncology, 2003, 21, 1440-1446.	1.6	92
244	Flexible Matching Strategies to Increase Power and Efficiency to Detect and Estimate Gene-Environment Interactions in Case-Control Studies. American Journal of Epidemiology, 2002, 155, 593-602.	3.4	32
245	The Performance of Methods for Correcting Measurement Error in Case-Control Studies. Epidemiology, 2002, 13, 507-516.	2.7	22
246	Clinical Diagnosis of Ischemic versus Hemorrhagic Stroke: Applicability of Existing Scores in the Emergency Situation and Proposal of a New Score. Neuroepidemiology, 2002, 21, 8-17.	2.3	24
247	Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. American Journal of Medicine, 2001, 111, 521-527.	1.5	44
248	Socio-demographic factors, health behavior and late-stage diagnosis of breast cancer in Germany. Journal of Clinical Epidemiology, 2001, 54, 719-727.	5.0	57
249	A Prospective Study of Blood Pressure and Risk of Cataract in Men. Annals of Epidemiology, 2001, 11, 104-110.	1.9	34
250	Nonsteroidal anti-inflammatory drugs and the kidney. Current Opinion in Nephrology and Hypertension, 2001, 10, 161-163.	2.0	18
251	Individual and joint contribution of family history andHelicobacter pylori infection to the risk of gastric carcinoma. Cancer, 2000, 88, 274-279.	4.1	129
252	Potential gain in efficiency and power to detect gene-environment interactions by matching in case-control studies. , 2000, 18, 63-80.		15

#	Article	IF	Citations
253	Obesity, overweight and patterns of osteoarthritis. Journal of Clinical Epidemiology, 2000, 53, 307-313.	5.0	290
254	Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study. Annals of Internal Medicine, 1998, 128, 713.	3.9	254
255	Construction Work and Low Back Disorder. Spine, 1997, 22, 2558-2563.	2.0	46
256	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	48
257	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	4
258	Caseâ€“crossover and caseâ€“timeâ€“control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 1997, 6, S51-S59.	1.9	73
259	Calcium Gluconate in Severe Verapamil Intoxication. New England Journal of Medicine, 1994, 330, 718-720.	27.0	38
260	Epidemiologic study of analgesic abuse: Mortality study in 7275 working women (1968â€“1987). Kidney International, 1991, 40, 728-733.	5.2	8
261	An Epidemiologic Study of Abuse of Analgesic Drugs. New England Journal of Medicine, 1991, 324, 155-160.	27.0	111